

This report contains summary data from the Prescription Drug Monitoring Program (PDMP). Data is provided as a courtesy for the board and is intended to be used for informational purposes only.

### Notices:

- The communications module will be rolling out by the end of the year.
- We are working with Appriss on being able to issue automatic compliance notifications to providers who directly dispense, letting them know if they miss a day of reporting.
- We received approval for the Provider Outlier Module and the module will be available by October.

### Registration

### Portal

Number of licensed Nurses: 1,490 Number of PDMP Nursing registrations: 1,124 (19 In-Process) Number with DEA Registrations: 1,186 (17 In-Process) Prescriptive Authority: 1,281 (7 In-process) Directly Dispensing Controlled Substances: 70 (183 prior to letter sent 4/12/21) Compliance rate (DEA and PDMP registrations): 95%

# AWARxE (PDMP)

Number registered with the PDMP: 1,155

### **Use – Review Compliance**

Federally scheduled II – III, over a three-day supply (some specialties omitted) Q1 2021: 47.28% - 21,537 dispensations; 10,182 searched Q2 2021: 52.15% - 22,017 dispensations; 11,481 searched

# MME Use (Q1/Q2 2021)

Number of patients treated with over 90 MME: 320 (13% increase from Q4 2020/Q1 2021) Number of patients treated with over 120 MME: 118 (16% decrease from Q4 2020/Q1 2021)

Number of patients treated with dangerous combinations (benzodiazepines and opioids): 504 (11% decrease from Q4 2020/Q1 2021)

Number of patients treated with dangerous combinations (benzodiazepines, opioids, carisoprodol): 8 (43% decrease from Q4 2020/Q1 2021)

### **Delinquent Reporters**

Providers who directly dispense are required to report daily. Letters were sent out on April 12, 2021 to clarify status. We are working with Appriss on a more efficient way to monitor reporting compliance. Details pending.

# Recommendations

- Encourage increased reviewing, including the use of delegates
- Set daily MME in regulation
- Provide guidance to licensees on prescribing practices related to the use of dangerous combinations

Contact: Lisa Sherrell | PDMP Manager | <u>akpdmp@alaska.gov</u> | 907-465-1039



• Develop a plan for following up with delinquent reporters

### **Contract Updates**

- A Communications Module allowing provider-to-provider communication within the PDMP will be launched soon. The quick start guide is complete, and instructions have been updated AWARxE user manual. Launch date TBD.
- We received approval to purchase the Provider Outlier Module. This module will identify prescribers whose prescribing habits could potentially have negative repercussions on their patients.
- We are continuing to discuss the Delinquent Reporting Notice with the states who have implemented the system and are anticipating enabling this feature once license renewals have completed. This enhancement will send notices to providers when at least one day of reporting is missed.

### MME Use

Q1/Q2 2021

The CDC recommends that primary care clinicians should reassess evidence of the benefits and risks to the individual when increasing dosage to greater or equal to 50 MME/day and avoid increasing to greater or equal to 90 MME/day when possible due to an increased risk of complications. The CDC also recommends avoiding concurrent benzodiazepine and opioid prescriptions, given the high risk of adverse drug-drug interactions, specifically respiratory depression and death.

CDC checklist for prescribing opioids -

https://www.commerce.alaska.gov/web/portals/5/pub/PDMP\_OpiodPrescribeCDC\_06.2018.pdf

CDC guidelines for prescribing opioids for chronic pain -

https://www.commerce.alaska.gov/web/portals/5/pub/PDMP\_OpiodPrescribeCDCPain\_2018.10.pdf

	# Providers	# Providers	# Providers	# Providers	Dangerous Combo	
Provider Type	Prescribing at Least Once	Who Reviewed 0 Patients	Prescribing >90MME	Prescribing >120MME	Benzo Opioid	Benzo Opioid Carisoprodol
DEN	333	54% (181)	6% (19)	2% (6)	26% (85)	0
MED	1282	29% (370)	21% (273)	13% (165)	33% (425)	2% (24)
NUR	543	18% (98)	11% (62)	8% (43)	25% (138)	1% (7)
OPT	5	80% (4)	0	0	0	0
PA	347	14% (49)	19% (67)	12% (41)	29% (99)	1% (4)
VET	193	73% (141)	4% (8)	3% (6)	5% (9)	0